Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05005403 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | recruiting | Phase 1 | 694 | AbbVieINDUSTRY | 6 | Jun 23, 2026 |
| clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT06479239 | Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer(Panc 002) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer(DUET-BTC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06278454 | Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases | recruiting | Phase 1 | 58 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT06158139 | Autologous CAR-T Cells Targeting B7-H3 in PDAC | recruiting | Phase 1 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07145450 | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | recruiting | Phase 1 / Phase 2 | 96 | Anocca ABOTHER_GOV | 4 | Jun 8, 2026 | clinicaltrials |
| NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07614061 | Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer | recruiting | Phase 1 | 18 | Shanghai Zhongshan HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT06427239 | Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 130 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | recruiting | Phase 1 / Phase 2 | 307 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07595835 | CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer(PANCOSIL) | recruiting | Phase 1 / Phase 2 | 20 | M.R. MeijerinkOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07481357 | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Dong-A ST Co., Ltd.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06904378 | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors | recruiting | Phase 1 | 48 | Shenzhen Xinhe BiomedicalINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 55 | West China HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06320990 | Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection(MCN_Tam) | recruiting | Phase 1 | 15 | University of NebraskaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06058663 | Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 | 16 | Mayo ClinicOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07549958 | PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC) | recruiting | Phase 1 | 18 | University of California, IrvineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212(TEADCO) | recruiting | Phase 1 / Phase 2 | 229 | Orion Corporation, Orion PharmaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Washington University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06844422 | Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) | recruiting | Phase 1 / Phase 2 | 37 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07353645 | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 49 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05257993 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 71 | Onconic Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06454383 | Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07114861 | The KN510713 Study in Combination With mFOLFIRINOX | recruiting | Phase 1 / Phase 2 | 30 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2026source: clinicaltrials